← Back to headlines

Genmab Stock Soars After Upgraded Revenue Forecast
Biotech company Genmab's shares surged on the stock market after it raised its annual revenue forecast, citing stronger-than-expected sales of several cancer medications.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.


